Overview of Polcrom

Polcrom: Identity, Active Ingredient, and Formulation

Polcrom is a specific trade name for a synthetic, single-ingredient anti-allergic medicinal product formulated as a sterile ophthalmic solution (eye drops). Its active compound is Sodium Cromoglycate, also known as Cromolyn sodium, a substance classified chemically as a chromone derivative. This medication is designed for ocular administration, ensuring targeted, local action on the eye surface.

The use of Sodium Cromoglycate in ophthalmology is utilized for managing allergic eye conditions. The formulation, being an aqueous solution, facilitates delivery of the compound to the conjunctiva, minimizing systemic exposure and differentiating it from oral antihistamines.

Pharmacological Class and General Purpose

Polcrom is classified pharmacologically as a mast cell stabilizer, a distinct type of anti-allergic agent. This class allows the medication to function primarily as a prophylactic treatment, meaning its value lies in preventing allergic symptoms from beginning, rather than treating an acute reaction after it has already occurred.

Its general therapeutic purpose is to help prevent the onset of symptoms associated with allergic conditions affecting the eye, notably allergic conjunctivitis. This preventative strategy is used in scenarios such as anticipated exposure to seasonal allergens like pollen, offering a method for symptom management.

Core Mechanism and Patient Benefit

The efficacy of the Polcrom formulation rests on the ability of Sodium Cromoglycate to inhibit the cellular event known as mast cell degranulation directly at the site of inflammation. By stabilizing the cell membrane, the active ingredient prevents the release of inflammatory chemicals, such as histamine and leukotrienes, when the eye encounters an allergen. This inhibitory action on mediator release is foundational to the drug's anti-allergic effect, providing a protective, prophylactic benefit for patients by stabilizing the immune response before symptoms become established.

Regulatory References

Cromolyn Ophthalmic: MedlinePlus Drug Information

What side effects are possible with Polcrom?

Possible Side Effects and Safety Information

The official safety profile for Polcrom (Sodium Cromoglycate ophthalmic solution) is primarily characterized by effects at the site of administration, consistent with its local action as a mast cell stabilizer. All documented adverse reactions and safety statements are classified according to regulatory standards from government health authorities.

Adverse Reactions Scope and Frequency

The most frequently reported adverse reaction attributed to the use of the eye drops is transient ocular stinging or burning immediately upon instillation. This effect is short-lived and generally localized. Other symptoms listed as infrequent events in regulatory documents, though their direct attribution is sometimes unclear, include conjunctival injection, watery eyes (lachrymation), itchy eyes, dryness around the eye, and eye irritation.

Rarely, the drug has been associated with immediate hypersensitivity reactions. These serious reactions, which involve systemic effects, include symptoms such as dyspnea (difficulty breathing), edema (swelling), and generalized rash.

Safety Considerations and Restrictions

Classification Category	Safety Note Documented in Regulatory Text
System-Organ Classes	Primarily Eye disorders; rarely Immune System and Respiratory (due to hypersensitivity).
Pediatric Use	Safety and effectiveness are not established in children below the age of 4 years.
Pregnancy/Lactation	Classified as Pregnancy Category B; it is not known if the drug is excreted in human milk.
Contraindication	Known hypersensitivity to sodium cromoglycate or any other component of the formulation.

These official safety statements structure the understanding of the medicine’s risk profile, focusing on expected local effects, rare systemic risks, and specific population constraints defined by clinical data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Polcrom (Sodium Cromoglycate Ophthalmic Solution) establish the drug's overdose profile based on its local route of administration and limited systemic exposure. The data indicates a low potential for systemic risk.

Documented Overdose Profile

Manifestation	Official Regulatory Statement
Systemic Toxicity	No toxic effect has been formally reported in the event of an overdose. The drug is poorly absorbed from both the eye and the gastrointestinal tract, contributing to its minimal systemic exposure profile.
Reported Cases	Regulatory labeling documents indicate that there have been no reported cases of overdosage with the ophthalmic solution.

Required Emergency Actions

For the management of a suspected drug overdose, government documents mandate the action to contact a regional poison control centre. Medical observation is recommended in all cases of overdosage, and the required procedural step is to institute symptomatic treatment. The official regulatory guidance specifies that in the event of excessive local administration to the eye, the affected area should be copiously washed with sterile physiologic serum. Urgent medical attention should also be sought for any intercurrent ocular condition, such as trauma or infection, that may occur while using the medication. This structure ensures that even with a low systemic risk profile, mandatory emergency procedures are in place.

Therapeutic Uses of Polcrom

What Polcrom treats: main uses and benefits

Polcrom is an ophthalmic medication used primarily to manage and prevent the symptoms of allergic conjunctivitis. It belongs to a group of medicines known as mast cell stabilizers, which work by preventing the release of natural substances in the eye that cause inflammation and allergic reactions.

Main Uses

The medication is indicated for the relief of eye symptoms associated with various forms of allergic inflammation, including:

Seasonal Allergic Conjunctivitis: Also known as hay fever, this condition occurs during specific times of the year when pollen counts from trees, grasses, or weeds are high.
Perennial Allergic Conjunctivitis: This involves year-round symptoms typically triggered by indoor allergens such as dust mites, pet dander, or mold spores.

Benefits and Action

Polcrom acts locally to address the underlying mechanism of the allergic response rather than just masking the symptoms. Its primary benefits include:

Reduction of Ocular Discomfort: It helps alleviate the persistent itching and burning sensations often associated with allergies.
Management of Redness and Swelling: By stabilizing mast cells, the medication reduces the localized inflammatory response that leads to blood vessel dilation and eyelid puffiness.
Control of Excessive Tearing: It helps normalize tear production that often becomes overactive during an allergic flare-up.
Preventative Action: When used consistently, the medication can help prevent the onset of severe symptoms before exposure to known allergens occurs.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Polcrom (Sodium Cromoglycate Ophthalmic Solution) is subject to specific population eligibility rules defined by regulatory agencies. Use is strictly contraindicated in any patient with known hypersensitivity to the active substance, Sodium Cromoglycate, or to any of the non-active ingredients (excipients) in the eye drop formulation. Certain regulatory documents also establish an absolute contraindication for use in children under 2 years of age.

The medicine's use is generally established for adults and older adults. Age-group eligibility for children varies by region, but the safety and effectiveness have not been established in those under 4 or 5 years of age.

A key eligibility-related restriction is imposed by the preservative, Benzalkonium Chloride: patients must refrain from wearing soft contact lenses while undergoing treatment.

Regarding physiological states, the drug should be used during pregnancy and lactation only if clearly needed, requiring caution due to insufficient human data. No specific restrictions related to renal or hepatic impairment are documented for the ophthalmic solution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Polcrom (Sodium Cromoglycate ophthalmic solution) is characterized by a minimal risk of systemic interactions. Government regulatory documentation confirms that because the active ingredient is poorly absorbed and not metabolized (less than 0.07% systemic absorption), no systemic drug-drug interactions are documented.

Ocular and Product Restrictions

While systemic interactions are absent, specific restrictions apply to co-administration with other ocular products and medical devices, as noted in the regulatory labeling.

Interaction Type	Requirement as per Official Labeling
Soft (Hydrophilic) Contact Lenses	Must not be worn during treatment when using formulations containing benzalkonium chloride.
Timing Separation	Lenses must be removed prior to drop instillation and not reinserted earlier than 15 minutes after use.
Other Ocular Treatments	Co-administration with any other eye medication requires the explicit direction of a physician.

Food, Alcohol, and Supplements: Official regulatory documents confirm no documented interactions with food, alcoholic beverages, herbal products, or dietary supplements.

Mechanism of Action

The action of Sodium Cromoglycate is mediated by a prophylactic mechanism that operates directly at the cellular level to preemptively modulate the IgE-mediated signaling cascade. Its function is strictly focused on stabilizing key immune cells to interrupt the initiation of the inflammatory cascade. The compound functions as a mast cell stabilizer, engaging a mechanism that inhibits the influx of calcium ions ( Ca^2+) into the sensitized mast cell. This molecular intervention prevents the Ca^2+ rise, which is the requisite trigger for the cell to release its contents. By preventing this influx, the mechanism maintains the integrity of the cell membrane and interrupts the propagation of the inflammatory signal.

This stabilization effect leads to a preemptive blockade of mast cell degranulation, thereby stopping the secretion of key inflammatory mediators, particularly histamine and leukotrienes. This action modifies the early molecular steps that would otherwise result in significant local tissue changes, reducing the release of excessive mediator concentrations, which alters the local physiological environment.

Dosage and Administration Information

Administration Method

Polcrom is typically administered as an ophthalmic solution. Proper technique is essential to ensure the substance is delivered effectively to the ocular surface.

Preparation

Before administration, hands should be thoroughly washed with soap and water to prevent contamination of the eye or the medication container. If the solution is provided in a multi-dose bottle, the cap should be removed without touching the dropper tip to any surface, including the eye or eyelids.

Application Steps

Positioning: Tilt the head back slightly or lie down. Look upward toward a fixed point.
Creating a Pocket: Using one finger, gently pull down the lower eyelid to create a small pocket between the eyelid and the eyeball.
Dispensing: Hold the container steady above the eye. Allow the prescribed number of drops to fall into the conjunctival sac (the pocket created by the lower lid). The tip of the dispenser must not make contact with the eye.
Closing the Eye: Close the eye gently for a brief period. Avoid blinking vigorously or rubbing the eye immediately after application.
Nasolacrimal Occlusion: Applying light pressure to the inner corner of the eye (near the nose) for approximately one minute can help keep the solution on the ocular surface by reducing drainage through the tear ducts.

Use with Contact Lenses

General practice suggests that contact lenses should be removed prior to the application of ophthalmic drops. Lenses can usually be reinserted after a specific interval, allowing the solution to be absorbed or cleared from the surface of the eye. Following the specific guidance provided regarding lens compatibility is necessary to prevent damage to the lenses or irritation to the eye.

Consistency of Use

For the substance to maintain its presence on the ocular surface, it is often administered at regular intervals throughout the day. Maintaining a consistent schedule helps ensure the eye remains in contact with the solution as intended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Polcrom

Evidence for Use in Seasonal Allergic Conjunctivitis

Research has explored Sodium Cromoglycate Ophthalmic Solution in studies for Seasonal Allergic Conjunctivitis (SAC) through numerous short-term randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms typical of allergy seasons, such as periods of high pollen counts. Researchers monitored adult and child populations with confirmed seasonal allergies, examining patient-reported outcomes describing perceived discomfort. Specifically, studies explored how outcomes related to symptoms, including ocular itching, redness, and excessive watering change over time.

Studies monitored how symptom patterns evolved in observed populations, noting differences between groups receiving the ophthalmic solution and those receiving placebo. Some trials described patterns related to the monitored use of supplemental oral anti-allergy medications among the observed populations. The overall structure of evidence for SAC contributes to the broader evidence landscape.

Long-term effects are not fully established because follow-up durations were limited in most formal RCTs. Comparative evidence is lacking for head-to-head assessments against certain other topical agents.

Evidence for Use in Chronic Allergic Conjunctivitis

This part details the structure of the evidence for managing allergic eye conditions associated with year-round exposure, encompassing both Perennial Allergic Conjunctivitis (PAC) and the more severe Vernal Keratoconjunctivitis (VKC).

Research on Perennial Allergic Conjunctivitis (PAC)

The research for Perennial Allergic Conjunctivitis (PAC) involves intermediate-term studies examining functional limitations and symptoms that may vary in intensity due to year-round allergens. Research explored symptom intensity or variability to observe patterns in chronic allergic signs. Data are still emerging regarding the sustained measurement of outcomes over extended periods. Data for long-term management remains insufficient, and most studies only provide context on short-term changes.

Research on Vernal Keratoconjunctivitis (VKC)

Research also explored the ophthalmic solution’s use in Vernal Keratoconjunctivitis (VKC), a more severe, chronic condition. Trial observations included data on the monitored use of supplementary corticosteroids among groups receiving the ophthalmic solution versus placebo. Limitations include that comparative evidence is lacking when assessing the medication against certain other anti-inflammatory agents used for VKC.

Remaining Research Gaps and Areas of Uncertainty

One key limitation is the lack of direct comparative evidence against certain other anti-allergic eye drops. Scientific literature has also pointed to the possibility of publication bias, suggesting that some findings may be overrepresented in the collective evidence. Certainty remains low regarding outcomes beyond the typical short-term study duration.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Polcrom (FAQ)

Q: What kind of conditions is Polcrom typically used for?

A: According to regulatory documents, Polcrom is officially indicated for the relief and treatment of various allergic eye conditions.

This includes common conditions such as seasonal allergic conjunctivitis (hay fever) and, in some clinical contexts, perennial allergic conjunctivitis and vernal keratoconjunctivitis (VKC).

Q: How quickly should I expect Polcrom to start working?

A: Official product information indicates that a change in symptoms, such as decreased itching or redness, is usually noted within 2 to 3 days of starting treatment.

The drug is intended for prophylactic (preventative) use, which typically involves initiating treatment before exposure to the allergen is expected to occur.

Q: Is Polcrom the same as or very similar to another drug I might know?

A: Polcrom contains the active substance Sodium Cromoglycate, which is classified as a Mast Cell Stabilizer.

This mechanism of action is distinct from common antihistamines. It is shared by a small class of other anti-allergy agents, though the exact formulation and active ingredient of Polcrom are unique to this product.

Q: Can Polcrom be used for symptoms other than the ones listed in the official uses?

A: The medication is officially indicated specifically for the management of allergic eye symptoms like itching, tearing, and redness.

If symptoms worsen or are not consistent with allergic reactions, guidance from a healthcare professional may be appropriate to determine the correct course of action.

Q: Can Polcrom cause drowsiness or affect alertness?

A: Official safety documents indicate that drowsiness is not a commonly reported side effect of these eye drops.

However, transient blurred vision may occur immediately after application. Official warnings recommend caution and waiting until vision is clear before driving or operating machinery.

Q: What is the typical time frame for side effects to appear after starting Polcrom?

A: The most frequently reported side effect—a transient stinging or burning—occurs immediately upon instillation and is usually short-lived.

The official product information does not specify the time frame for other, less common side effects to appear after starting treatment.

Q: Is Polcrom effective for non-allergic symptoms?

A: The medicine's action is specific to the body's reaginic (immediate type) antigen/antibody reactions, and it is indicated exclusively for the management of allergic eye conditions.

It is not officially indicated to treat general eye irritation or other non-allergic eye symptoms.

Q: How does the mechanism of Polcrom differ from an allergy shot?

A: Polcrom is a mast cell stabilizer that works locally at the eye surface to prevent the release of allergic mediators like histamine.

In contrast, an allergy shot (immunotherapy) is a systemic treatment that involves administering doses of an allergen over time to help the entire body's immune system build tolerance.

Q: Is it normal to feel a mild burning sensation when first using Polcrom?

A: Regulatory documents describe a transient stinging or burning sensation upon instillation as a frequently reported adverse reaction associated with the use of the eye drops.

This immediate, temporary effect is considered expected based on the medication's safety profile.

Q: What is the recommended duration of a single course of Polcrom therapy?

A: The medication is typically intended for continuous use throughout the period when an individual is exposed to the relevant allergen, such as an entire pollen season.

Some clinical sources suggest that treatment of several weeks may be suggested to maintain the effect during the exposure period.

Q: Is Polcrom available without a prescription in most places?

A: According to regulatory labeling in many jurisdictions, formulations containing 2% Sodium Cromoglycate are authorized for sale without a prescription (Over-The-Counter or OTC).

However, availability and dispensing rules may vary based on local regulations.

Q: Do official documents mention any risk of overdose with Polcrom?

A: Due to the eye drops' minimal systemic absorption (less than 0.07%), official regulatory toxicology profiles consider the risk of serious overdose from the topical administration of Polcrom to be negligible.

The active ingredient is poorly absorbed into the body, minimizing the potential for systemic effects.

Q: Is Polcrom safe to use during pregnancy according to official sources?

A: Official documents state that use in pregnancy is reserved for situations where the potential benefit is judged to outweigh the potential risk.

While general experience has not suggested adverse effects on fetal development, caution is typically advised, particularly during the first three months of pregnancy.

Q: Are there any special warnings for Polcrom use in women who are breastfeeding?

A: Official regulatory text states that it is not known whether the drug is excreted into human breast milk.

For this reason, regulatory warnings indicate that caution is advised when the eye drops are administered to a nursing mother.

Q: What happens if I stop using Polcrom suddenly?

A: Polcrom is a prophylactic agent, meaning it works by preventing symptoms before they start.

Official warnings suggest that if the continuous use of the treatment is abruptly stopped or significantly reduced, the underlying allergic symptoms of the condition may return.

Q: Can children of all ages use Polcrom?

A: Official regulatory documents generally state that the safety and effectiveness of Polcrom have not been established in children under 4 or 5 years of age.

Eligibility for use in younger children is determined by a healthcare provider based on age and regional labeling requirements.

Q: Are there any reports of Polcrom interfering with laboratory test results?

A: Official product information states that no systemic drug-drug interactions are documented.

There are no specific warnings in regulatory documents about the medication interfering with routine blood or urine laboratory tests.

Q: Is it necessary to shake Polcrom before using it?

A: The official administration instructions detail the steps for proper application of the eye drops, including aseptic technique.

These regulatory instructions do not mention any requirement to shake the ophthalmic solution before instillation.

Q: Do any official warnings exist about driving or operating machinery while using Polcrom?

A: Yes, official warnings advise that if an individual experiences transient blurred vision immediately following the application of the eye drops, caution is necessary.

It is recommended to wait until vision has cleared completely before driving or resuming activities that require clear vision.

How should Polcrom be stored and disposed of?

How to Store and Dispose of Polcrom

Polcrom (cromolyn sodium ophthalmic solution) must be stored under specific environmental and handling conditions defined in regulatory labeling to maintain product stability and sterility.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, between mathbf20^circ to mathbf25^circC (mathbf68^circ to mathbf77^circF).
Protection	Protect from light and store in its original carton.
Handling	Keep tightly closed.
Safety	Keep out of the reach of children.

Disposal

Official instructions require that any remaining contents of the ophthalmic solution be discarded after the prescribed treatment period to minimize contamination risk and ensure quality.

Polcrom